Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neuromyelitis optica markets reached a value of US$ 299.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 469.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.17% during 2024-2034.
The neuromyelitis optica market has been comprehensively analyzed in IMARC's new report titled "Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuromyelitis optica refers to a rare autoimmune disease affecting the central nervous system, specifically the optic nerves and spinal cord. In this case, the immune system attacks the myelin sheath that protects the nerve fibers, leading to inflammation, demyelination, and nerve damage. The common indications of the ailment include weakness or numbness in the arms and legs, pain in the eyes, loss of vision, paralysis of the legs and arms, difficulty controlling the bladder or bowels, etc. Individuals suffering from neuromyelitis optica may also experience confusion, spasticity, sexual dysfunction, hearing loss, uncontrollable hiccups or itching, vertigo, etc. The diagnosis of this condition is based on a review of the patient's symptoms, along with a neurological and physical exam. Several diagnostic imaging studies are utilized to identify lesions in the spinal cord and optic nerves that are characteristic of the ailment. Additionally, various laboratory tests are performed to detect the presence of antibodies that target a protein called aquaporin-4 (AQP4), which are present in most patients. In some cases, a spinal tap (lumbar puncture) is also done to analyze the cerebrospinal fluid for signs of inflammation.
The rising cases of autoimmune disorders, which cause the body's defense system to attack healthy cells by defect, are primarily driving the neuromyelitis optica market. In addition to this, the escalating prevalence of various risk factors, such as vitamin D deficiency, chain smoking, gastrointestinal infections, etc., is also bolstering the market growth. Furthermore, the widespread adoption of immunosuppressive drugs, including mycophenolate mofetil and rituximab, for treating the disease is acting as another significant growth-inducing factor. These agents mainly target T and B cell functions to eliminate proinflammatory molecules from the peripheral bloodstream and prevent attacks. Additionally, several key players are making extensive investments in R&D activities to launch novel technologies that facilitate an improved understanding of the immunopathological mechanisms underlying the illness. This, in turn, is creating a positive outlook for the market. Moreover, the emerging popularity of monoclonal antibodies, such as anti-CD19 and anti-interleukin-6, owing to their numerous advantages, including enhanced safety, lower toxicity, and improved patient outcomes, is further expected to drive the neuromyelitis optica market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the neuromyelitis optica market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuromyelitis optica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuromyelitis optica market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuromyelitis optica market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuromyelitis optica market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuromyelitis optica marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuromyelitis optica market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuromyelitis optica market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuromyelitis optica market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuromyelitis optica across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuromyelitis optica by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuromyelitis optica by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neuromyelitis optica across the seven major markets?
What is the size of the neuromyelitis optica patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuromyelitis optica?
What will be the growth rate of patients across the seven major markets?
Neuromyelitis Optica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuromyelitis optica drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuromyelitis optica market?
What are the key regulatory events related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by status related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by phase related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by route of administration related to the neuromyelitis optica market?
The neuromyelitis optica market has been comprehensively analyzed in IMARC's new report titled "Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuromyelitis optica refers to a rare autoimmune disease affecting the central nervous system, specifically the optic nerves and spinal cord. In this case, the immune system attacks the myelin sheath that protects the nerve fibers, leading to inflammation, demyelination, and nerve damage. The common indications of the ailment include weakness or numbness in the arms and legs, pain in the eyes, loss of vision, paralysis of the legs and arms, difficulty controlling the bladder or bowels, etc. Individuals suffering from neuromyelitis optica may also experience confusion, spasticity, sexual dysfunction, hearing loss, uncontrollable hiccups or itching, vertigo, etc. The diagnosis of this condition is based on a review of the patient's symptoms, along with a neurological and physical exam. Several diagnostic imaging studies are utilized to identify lesions in the spinal cord and optic nerves that are characteristic of the ailment. Additionally, various laboratory tests are performed to detect the presence of antibodies that target a protein called aquaporin-4 (AQP4), which are present in most patients. In some cases, a spinal tap (lumbar puncture) is also done to analyze the cerebrospinal fluid for signs of inflammation.
The rising cases of autoimmune disorders, which cause the body's defense system to attack healthy cells by defect, are primarily driving the neuromyelitis optica market. In addition to this, the escalating prevalence of various risk factors, such as vitamin D deficiency, chain smoking, gastrointestinal infections, etc., is also bolstering the market growth. Furthermore, the widespread adoption of immunosuppressive drugs, including mycophenolate mofetil and rituximab, for treating the disease is acting as another significant growth-inducing factor. These agents mainly target T and B cell functions to eliminate proinflammatory molecules from the peripheral bloodstream and prevent attacks. Additionally, several key players are making extensive investments in R&D activities to launch novel technologies that facilitate an improved understanding of the immunopathological mechanisms underlying the illness. This, in turn, is creating a positive outlook for the market. Moreover, the emerging popularity of monoclonal antibodies, such as anti-CD19 and anti-interleukin-6, owing to their numerous advantages, including enhanced safety, lower toxicity, and improved patient outcomes, is further expected to drive the neuromyelitis optica market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the neuromyelitis optica market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuromyelitis optica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuromyelitis optica market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuromyelitis optica market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuromyelitis optica market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuromyelitis optica marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuromyelitis optica market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuromyelitis optica market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuromyelitis optica market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuromyelitis optica across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuromyelitis optica by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuromyelitis optica by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neuromyelitis optica across the seven major markets?
What is the size of the neuromyelitis optica patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuromyelitis optica?
What will be the growth rate of patients across the seven major markets?
Neuromyelitis Optica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuromyelitis optica drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuromyelitis optica market?
What are the key regulatory events related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by status related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by phase related to the neuromyelitis optica market?
What is the structure of clinical trial landscape by route of administration related to the neuromyelitis optica market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROMYELITIS OPTICA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROMYELITIS OPTICA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROMYELITIS OPTICA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEUROMYELITIS OPTICA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROMYELITIS OPTICA - UNMET NEEDS
10 NEUROMYELITIS OPTICA - KEY ENDPOINTS OF TREATMENT
11 NEUROMYELITIS OPTICA - MARKETED PRODUCTS
11.1 List of Neuromyelitis Optica Marketed Drugs Across the Top 7 Markets
11.1.1 Soliris (Eculizumab) - Alexion AstraZencea Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Uplizna (Inebilizumab) - Viela Bio
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Enspryng (Satralizumab) - Chugai Pharmaceuticals/Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROMYELITIS OPTICA - PIPELINE DRUGS
12.1 List of Neuromyelitis Optica Pipeline Drugs Across the Top 7 Markets
12.1.1 Ravulizumab - Alexion AstraZeneca Rare Disease
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Divozilimab - Biocad
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 RC18 - RemeGen
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 HBM9161 - HanAll Biopharma/Harbour BioMed/Immunovant
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SHR1459 - Eternity Bioscience/TG Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROMYELITIS OPTICA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROMYELITIS OPTICA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROMYELITIS OPTICA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuromyelitis Optica - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuromyelitis Optica - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuromyelitis Optica - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuromyelitis Optica - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuromyelitis Optica - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuromyelitis Optica - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuromyelitis Optica - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuromyelitis Optica - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuromyelitis Optica - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuromyelitis Optica - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuromyelitis Optica - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuromyelitis Optica - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuromyelitis Optica - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuromyelitis Optica - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuromyelitis Optica - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuromyelitis Optica - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuromyelitis Optica - Access and Reimbursement Overview
16 NEUROMYELITIS OPTICA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROMYELITIS OPTICA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROMYELITIS OPTICA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROMYELITIS OPTICA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROMYELITIS OPTICA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROMYELITIS OPTICA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEUROMYELITIS OPTICA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROMYELITIS OPTICA - UNMET NEEDS
10 NEUROMYELITIS OPTICA - KEY ENDPOINTS OF TREATMENT
11 NEUROMYELITIS OPTICA - MARKETED PRODUCTS
11.1 List of Neuromyelitis Optica Marketed Drugs Across the Top 7 Markets
11.1.1 Soliris (Eculizumab) - Alexion AstraZencea Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Uplizna (Inebilizumab) - Viela Bio
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Enspryng (Satralizumab) - Chugai Pharmaceuticals/Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROMYELITIS OPTICA - PIPELINE DRUGS
12.1 List of Neuromyelitis Optica Pipeline Drugs Across the Top 7 Markets
12.1.1 Ravulizumab - Alexion AstraZeneca Rare Disease
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Divozilimab - Biocad
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 RC18 - RemeGen
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 HBM9161 - HanAll Biopharma/Harbour BioMed/Immunovant
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SHR1459 - Eternity Bioscience/TG Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROMYELITIS OPTICA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROMYELITIS OPTICA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROMYELITIS OPTICA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuromyelitis Optica - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuromyelitis Optica - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuromyelitis Optica - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuromyelitis Optica - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuromyelitis Optica - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuromyelitis Optica - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuromyelitis Optica - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuromyelitis Optica - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuromyelitis Optica - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuromyelitis Optica - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuromyelitis Optica - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuromyelitis Optica - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuromyelitis Optica - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuromyelitis Optica - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuromyelitis Optica - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuromyelitis Optica - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuromyelitis Optica - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuromyelitis Optica - Access and Reimbursement Overview
16 NEUROMYELITIS OPTICA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROMYELITIS OPTICA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROMYELITIS OPTICA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
